Search
forLearn
5 / 801 resultslearn copper tripeptide-1
learn sh-Polypeptide-7
learn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
Research
5 / 104 results
research Pitx2, a β-catenin-regulated transcription factor, regulates the differentiation of outer root sheath cells cultured in vitro
Pitx2 helps outer root sheath cells differentiate but can't start hair growth on its own.
research miR-200a Targets PITX2 to Mediate Goose Fibroblast Proliferation Through the Wnt Pathway
miR-200a reduces goose fibroblast growth by targeting PITX2 in the Wnt pathway.
research Association between PITX2 polymorphism and androgenetic alopecia in the Indian population
Certain gene variations in PITX2 are linked to a higher risk of male pattern baldness in Indians.
research Effect of Nutritional Restriction on the Hair Follicles Development and Skin Transcriptome of Chinese Merino Sheep
Poor maternal nutrition can lead to fewer wool follicles in Chinese Merino sheep.
research 609 Symmetry breaking of tissue mechanics in wound induced hair follicle regeneration
Activating TRPA1 reduces scarring and promotes tissue regeneration.
Community Join
5 / 1000+ resultscommunity Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
community Waiting to start treatment until Kintor KX-826 Phase 2 data is published?
People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.
community KX-826 1% Phase II Results from China Just Dropped
KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.
community Kintor’s KX-826 Pyrilutamide!!
KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.
community KX-826 Phase II Results Just Dropped (Male AGA) – Key Takeaways
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.